deucravacitinib

Okubo Y, Morita A, Tada Y, Imafuku S, Armstrong AW, Blauvelt A, Vaile J, Popmihajlov Z, Li J, Sawant R, Habiro K, Tsuritani K, Ohtsuki[...]

Shah M, DeBusk L, Bohman MH, Rosenberg A, Burshtein J, Zakria D, Armstrong A, Boh E, Gottlieb AB, Khattri S, Litchman G, Merola J, Murina[...]

Armstrong AW, Warren RB, Sofen H, Spelman L, Linaberry M, Becker B, Jou YM, Daamen C, Kimball AB. Deucravacitinib in Plaque Psoriasis After Inadequate Response[...]

Armstrong AW, Kircik L, Stein Gold L, Strober B, De Oliveira CHMC, Vaile J, Jou YM, Daamen C, Scharnitz T, Lebwohl M. Deucravacitinib: Laboratory Parameters[...]

Merola JF, Ferris LK, Sobell JM, Sofen H, Osborne J, Vaile J, Jou YM, Daamen C, Scotto J, Scharnitz T, Lebwohl M. Deucravacitinib: Adverse Events[...]

Tsai TF, Tada Y, Kung C, Zhong Y, Cichewicz A, Borkowska K, Westley T, Kisa RM, Huang YH, Gao XH, Jo SJ, Armstrong AW. Indirect[...]

Korman NJ, Warren RB, Bagel J, Armstrong AW, Gooderham M, Strober B, Thaçi D, Morita A, Imafuku S, Foley P, Sofen H, Zheng M, Hippeli[...]

Armstrong AW, Park SH, Patel V, Nicolas P, Wang WJ, Colombo MJ, Chirikov V. Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to[...]

Vaccination Recommendations for Adults Receiving Biologics and Oral Therapies for Psoriasis and Psoriatic Arthritis: Delphi Consensus from the Medical Board of the National Psoriasis Foundation[...]

Kingston P, Blauvelt A, Strober B, Armstrong AW. Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis. J Psoriasis Psoriatic Arthritis. 2023 Oct;8(4):156-165.[...]